Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate.

@article{Hoekstra2005IntermittentRI,
  title={Intermittent rises in plasma homocysteine in patients with rheumatoid arthritis treated with higher dose methotrexate.},
  author={Monique Hoekstra and Cees J. Haagsma and C J A Doelman and Mart Afj van de Laar},
  journal={Annals of the rheumatic diseases},
  year={2005},
  volume={64 1},
  pages={
          141-3
        }
}
OBJECTIVES To investigate the effect of higher weekly maintenance dose methotrexate (MTX) (> or =25 mg/week) on plasma homocysteine concentrations in adults with RA. METHODS Patients with RA were treated with high doses of MTX with adjuvant folic acid. Plasma homocysteine was determined at baseline and 1, 2, 4, 8, 12, and 48 hours after subcutaneous MTX administration. Maximum homocysteine concentrations after MTX administration were compared with baseline concentrations. RESULTS Fifteen… Expand
DOES SHORT-TERM LOW-DOSE METHOTREXATE TREATMENT AFFECT HOMOCYSTEINE BLOOD LEVEL IN PATIENTS WITH PSORIASIS?
TLDR
A study to evaluate the plasma levels of homocysteine, vitamin B12 and folate in patients with psoriasis before and after short-term low-dose methotrexate treatment found no significant difference. Expand
Homocysteine and lipid profile in children with Juvenile Idiopathic Arthritis
TLDR
JIA patients do not present significant increased concentration of Hcy despite the use of MTX, probably due to the folate supplementation, and the mild abnormalities in the lipidogram may reflect a current concern with diet and health. Expand
Association of Plasma Homocysteine Level and Carotid Intima-Media Thickness in Rheumatoid Arthritis Patients Receiving Methotrexate
TLDR
According to the study results, methotrexate treatment in female patients with RA increases plasma homocysteine levels and prevalence of atherosclerotic plaque, which may be a cause of Atherosclerosis. Expand
Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis
TLDR
Time-varying methotrexate (MTX) use and risk of cardiovascular events (CVE) in patients with rheumatoid arthritis diagnosed after their 65th birthday was evaluated and about a 20% decrease in CVE was observed associated with recent continuous MTX use. Expand
Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity.
BACKGROUND The polymorphism of thymidylate synthase (TS) gene and homocysteine are reported to have a relationship to methotrexate (MTX) metabolism, with conflicting results. The aim of this studyExpand
Folate supplementation during methotrexate therapy for rheumatoid arthritis.
TLDR
Clinical trials related to folate supplementation during MTX therapy for RA are reviewed, finding that FA supplementation has a beneficial effect on homocysteine (hcy) metabolism and may prevent the formation of the less effective metabolite 7-hydroxy-MTX. Expand
Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis.
TLDR
Poor vitamin B-6 status and elevated plasma homocysteine concentrations were seen in older women with rheumatoid arthritis compared to healthy controls and may contribute to their increased risk of cardiovascular disease. Expand
Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients
TLDR
The MTHFR 677TT genotype is an independent risk factor for HHC in Tunisians RA patients, and could be a useful marker of MTX toxicity in RA patients. Expand
Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis
TLDR
The data show a high prevalence of hyperhomocysteinaemia in Mexican patients with RA, and more effort is required to evaluate and treat earlier this coronary risk factor. Expand
Are Rheumatoid Arthritis Patients More Vulnerable To Cardiovascular Disease?
Increased mortality rate because of Cardiovascular Disease [CVD] is well established in Rheumatoid Arthritis [RA] patients. We have estimated the role of serum malondialdehyde [MDA] and homocysteineExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 16 REFERENCES
Changes in plasma homocysteine in arthritis patients starting treatment with low-dose methotrexate subsequently supplemented with folic acid
  • O. Slot
  • Medicine
  • Scandinavian journal of rheumatology
  • 2001
TLDR
It is concluded that treatment with MTX induces a significant rise in p-homocysteine that is neutralised by FA supplementation, and Supplementation with FA from the start of MTX treatment is recommended considering the increased risk of cardiovascular disease that is associated with elevated concentrations of p-Homocysteines. Expand
Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
TLDR
Low-dose MTX treatment in RA patients leads to an increased plasma homocysteine level, which protects against potential cardiovascular risks, and the influence of the C677T mutation in the methylenetetrahydrofolate reductase gene (MTHFR) on the change in plasma homocrysteine levels duringMTX treatment. Expand
Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis
TLDR
A persistent increase in plasma homocysteine concentrations was observed in patients treated with MTX alone and more pronounced in combination with SSZ, in contrast withSSZ alone. Expand
Fasting plasma homocysteine as a sensitive parameter of antifolate effect: A study of psoriasis patients receiving low‐dose methotrexate treatment
TLDR
The level of fasting plasma homocysteine was shown to be a sensitive and responsive parameter of antifolate drug treatment and did not affect the plasma profile for homocy steine after methionine loading. Expand
Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis.
TLDR
Bioavailability of a higher oral dose of MTX in adult patients with RA is highly variable, and on average two-thirds that of the subcutaneous administration, and a change to parenteral administration should be considered. Expand
Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.
TLDR
For longterm, low dose MTX therapy, there are now at least 3 reasons to consider supplementation with folic acid (a low cost prescription): to prevent MTX toxicity, to prevent or treat folate deficiency, and to prevent hyperhomocysteinemia. Expand
Abnormal homocysteine metabolism in rheumatoid arthritis.
TLDR
Elevated tHcy levels occur commonly in patients with RA, and may explain some of the increased cardiovascular mortality seen in such patients, and studies of the prevalence and mechanism of hyperhomocysteinemia in RA are warranted. Expand
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
TLDR
The data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality, which would set a standard against which new disease-modifying antirheumatic drugs could be compared. Expand
Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention.
TLDR
The epidemiological, genetic, and animal evidence together indicate that the association between serum homocysteine level and ischemic heart disease (IHD) is likely to be causal. Expand
Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95.
TLDR
The elevated mortality rates in RA patients compared to the general population have decreased during the last 20 years, possibly due to an increased access to specialized rheumatology care. Expand
...
1
2
...